Our group has continued to work on our main overarching project the Migraine Adaptive Brain Program.
Migraine is complex hereditary brain disorder, which helps us understand how the brain communicates and adapts to change through the sensory processing of internal and external stimuli. Our mission is to study brain function by analyzing how neural networks adapt, respond and communicate with cognitive circuits and the environment through sensory networks, and to transfer this knowledge to diagnose, treat and prevent brain disorders, such as migraine. We also aim to develop evidence-based approaches to enhance individual abilities and non-cognitive skills, and improve brain sense technological devices, with the ultimate goal of promoting self-knowledge and globally increasing the quality of life. Once these functions are better understood we will improve individual abilities and develop therapeutic solutions.

Group Leader
Patricia Pozo Rosich

Principal Investigator (PI)
Patricia Pozo Rosich

Marta Torres Ferrús, Adrià Vilà Balló, Xim Cerdà Company, Nara Ikumi Montserrat, Marta Vila Pueyo, Erika Ivanna Araya

PhD Students
Alicia Alpuente Ruiz, Angela Barbara Martí Marca, Edoardo Caronna, Victor José Gallardo López

Lab Technicians
Laila Asskour

Nursing and Technical Staff
Eulalia Giné Cipres, Myriam Olivé Díaz, Anna de la Torre Suñé, Victor José Gallardo López, Albert Muñoz Vendrell








Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW
Migraine: integrated approaches to clinical management and emerging treatments.
Lancet. 2021 Apr 17;397(10283):1505-1518
DOI: 10.1016/S0140-6736(20)32342-4
IF: 79.323

Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB
Migraine: epidemiology and systems of care
Lancet. 2021 Apr 17;397(10283):1485-1495
DOI: 10.1016/S0140-6736(20)32160-7
IF: 79.323

Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
J Headache Pain. 2021 Oct 7;22(1):120
DOI: 10.1186/s10194-021-01328-1
IF: 7.277

Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
J Headache Pain. 2021 Dec 13;22(1):151
DOI: 10.1186/s10194-021-01366-9
IF: 7.277

Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borrós G, Alpuente A, Caronna E, Vila-Balló A, Lorenzo-Bosquet C, Castell-Conesa J, Rovira A, Pozo-Rosich P
Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study
J Headache Pain. 2021 Jul 17;22(1):75
DOI: 10.1186/s10194-021-01289-5
IF: 7.277

SYNCHRO: Sense, rhYthm & Networks: the study of how erenumab modulates CHROnic migraine.
Principal Investigator: Patricia Pozo Rosich
Agency: Novartis
Funding: 230,000€
Period: 2020-2021

BIOMIGA: A multidisciplinary approach to the identification of BIOmarkers of MIGraine: a proof of concept study based on the stratification of responders to CGRP monoclonal Antibodies.
Principal Investigator: Patricia Pozo Rosich
Agency: Instituto de Salud Carlos III/ERANet Neuron
Funding: 100,000€ VHIR/690,000€ Global
Period: 2020-2022

AhEAD: Algoritmo de predicción de Eficacia de Respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos.
Principal Investigator: Patricia Pozo Rosich
Agency: Instituto de Salud Carlos III– ISCIII (FIS)
Funding: 87,120€
Period: 2020-2022

Mecanismos, modulación y terapia del dolor crónico
Principal Investigator: Patricia Pozo Rosich
Agency: Generalitat de Catalunya
Funding: 131,250€
Period: 2020-2022